UNCLASSIFIED

AD NUMBER ADB262451 **NEW LIMITATION CHANGE** TO Approved for public release, distribution unlimited **FROM** Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Nov 99. Other requests shall be referred to US Army Medical Research and Materiel Comd., Fort Detrick, MD 21702-5012. **AUTHORITY** USAMRMC ltr, 21 Feb 2003

ΑD			

Award Number: DAMD17-98-1-8202

TITLE: The Estrogen Receptor and Its Variants as Risk Factors in

Breast Cancer

PRINCIPAL INVESTIGATOR: Leigh Murphy, Ph.D.

CONTRACTING ORGANIZATION: University of Manitoba

Winnipeg, Manitoba R3T2N2 Canada

REPORT DATE: November 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Nov 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010122 093

NOTICE

DRAWINGS, SPECIFICATIONS, OR OTHER USING GOVERNMENT DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER NOT GOVERNMENT PROCUREMENT DOES IN ANY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS. SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-98-1-8202

Organization: University of Manitoba

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of

reducing this burden to washington Headquarters Management and Budget, Paperwork Reduction P	roject (0704-0188), Washington, DC 20503	ons and Reports, 1215 Jellerson Davis	righway, Suite 1204, At	lington, VA 22202-4502, and to the Office of
1. AGENCY USE ONLY (Leave	2. REPORT DATE	3. REPORT TYPE AND	DATES COVERI	ED
blank)	November 1999	Annual (01 Oct	98 - 01 Oct	99)
4. TITLE AND SUBTITLE			5. FUNDING N	UMBERS
The Estrogen Receptor and	Its Variants as Risk Fact	ors in Breast Cancer	DAMD17-98-	1-8202
J 1				
6. AUTHOR(S)			1	
Leigh Murphy, Ph.D.			1	
7. PERFORMING ORGANIZATION N	AME(S) AND ADDRESS(ES)			G ORGANIZATION
University of Manitoba			REPORT NU	MBER
Winnipeg, Manitoba R3T2N2 Car	ıada			
e-mail:				
lcmurph@cc.umanitoba.ca			}	
1				
9. SPONSORING / MONITORING AC	ENCY NAME(S) AND ADDRESS	S(ES)		NG / MONITORING EPORT NUMBER
ITS Amery Madical Bassamah and	Material Command	(AGENCYR	EPORT NUMBER
U.S. Army Medical Research and Fort Detrick, Maryland 21702-50				
For Deinck, Maryland 21702-30	12			
,			1.	
11. SUPPLEMENTARY NOTES				
12a, DISTRIBUTION / AVAILABILITY	STATEMENT			12b. DISTRIBUTION CODE
Distribution authorized to		only (proprietor-		
information, Nov 99) Othe				<u> </u>
to U.S. Army Medical Resear				

13. ABSTRACT (Maximum 200 Words)

Fort Detrick, Maryland 21702-5012.

The overall goal of this research is to understand how the estrogen receptor (ER) signal transduction pathway is altered during breast tumorigenesis and if enhanced and/or aberrant ER signal transduction increases the risk of developing breast cancer. Our previous data suggested that altered expression of ER α , ER β and their variants occurs during breast tumorigenesis. Our current data suggest that expression of cofactors which enhance ER activity, i.e. SRA, is increased during breast tumorigenesis while expression of cofactors which can repress ER activity, i.e. REA, either does not change or is not increased to a similar extent during breast tumorigenesis. Overall the data support the hypothesis that a substantial alteration of estrogen signaling pathways occurs during human breast tumorigenesis. In addition both our previous and our current data provide a very strong rationale to determine in parallel ER isoform/variant expression and cofactor expression during the early stages of preneoplastic progression that precede the onset of invasive breast cancer and determine if differences exist between normal women and patients who develop breast cancer, in order to assess a potential role in increasing the risk of invasive breast cancer. Identification, retrieval, review and collection of appropriate tissues blocks from a preliminary group of cases/controls in the Manitoba Breast Event Database has been completed and analyses of these tissue sections is in progress.

14. SUBJECT TERMS Breast Cancer , estro	gen receptor, variants, isofor	rms, cofactors, pre-	15. NUMBER OF PAGES 47
invasive lesio	ns, preneoplastic lesions, pat		16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Limited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. Z39-18 298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army. Where copyrighted material is quoted, permission has been obtained to use such material. Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material. Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations. ____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985). For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46. In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health. In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules. In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories. whenly 27 October 1949

4. TABLE OF CONTENTS.

		Page No.
1.	Front Cover	1
2.	SF 298 Report Documentation Page	2
3.	Foreword	3
4.	Table of Contents	4
5.	Introduction	5
6.	Body	6-9
7.	Key Research Accomplishments	9
8.	Reportable Outcomes	9-10
9.	Conclusions	10
10.	References	10-11
11.	Appendix 1	12-18
12.	Appendix 2	19
13.	Appendix 3	
14.	Appendix 4	

5. INTRODUCTION:

The overall goal of this research is to understand how the estrogen receptor signal transduction pathway is altered during breast tumorigenesis and if enhanced and/or aberrant ER signal transduction increases the risk of developing breast cancer.

Current dogma suggests that the steroid hormone, estrogen and its cellular mechanism of action have a major role in both the development and progression of human breast cancer. The estrogen receptor (ER) is a key component in this mechanism which undergoes an apparent increase in level of expression and likely a corresponding increase in signal transduction during tumorigenesis. We and others have compelling evidence to suggest that the expression of the ER, its variants and other isoforms are altered during breast tumorigenesis (1-5). While the expression of specific ER variants and/or isoforms and their overall prevalence relative to wild type ER is different between normal and neoplastic tissue, the pathophysiological significance of these ER variants/isoforms and their potential influence in modulation of the ER pathway in early progression of human breast cancer is not known. We propose to test the hypothesis that increased ER expression and altered ER variant and/or isoform expression cause enhanced and/or aberrant ER signal transduction in breast epithelial cells. We propose that such factors are altered during the early stages of pre-neoplastic progression that precede the onset of invasive breast cancer and are associated with an increased risk of developing breast cancer. Furthermore, in addition to the complexity of the ER-like molecules that may be expressed in target tissues. there is an increasing complexity of factors which can modulate the transcriptional activity of ER which in turn could alter ER signal transduction pathways (6). Recent identification of several of these cofactors (coactivators and corepressors) which can directly modulate the transcriptional activity of ER (7-10), provides compelling rationale to examine their expression in parallel to the studies we have proposed.

Our specific aim is to determine if alteration of ER signal transduction and ER variant and/or isoform expression occurs during the early stages of preneoplastic progression that precede the onset of invasive breast cancer and determine if differences exist between normal women and patients who develop breast cancer. A case/control retrospective study will be undertaken in which we

will examine ER in comparable breast epithelium and lesions (normal small ducts, benign non-proliferative lesions (adenosis), benign proliferative ductal hyperplasia (PDWA), and ductal carcinoma in situ (DCIS)} in women with or without invasive cancer. ER level will be assessed immunohistochemically, ER-beta mRNA expression will be measured by in situ hybridization, ER function will be assessed by measurement of progesterone receptor and pS2 expression and ER influence on proliferation rate will be assessed immunohistochemical measurement of Ki-67 in serial paraffin sections. Other factors which have been recently identified to modify ER activity include cyclin D (11), MAP kinase (12), several cofactors such as SRA (9), REA (10), and AIB1 (7). These will be assessed in parallel using antibodies, if available, and in situ hybridization. We will also study variant ER mRNA expression in parallel sections from frozen tissue blocks, where possible, by specific RT-PCR assays to detect deleted and truncated ER variants, to determine their relative expression with respect to the wild-type ER mRNAs and assess their potential role in altered ER signaling activity.

6. BODY:

Task 1.

Retrospective study of breast tissue samples. Immunohistochemical and *in situ* hydridization analysis of estrogen receptor signal transduction.

1. We have identified blocks within pathology department archives from one of two selected centers. These blocks contain specific lesions for study and these have now been obtained from St Boniface Hospital as a set of over 300 blocks for this study. A similar retrieval exercise is also underway at a second selected center (The Grace Hospital, Winnipeg) to ensure sufficient cases for the study. Details of these cases are shown on the attached spread sheets (appendix 1). The Manitoba Breast Event Registry (MBED) within the Manitoba Breast Tumor Bank was initially queried for all cases occurring at one center (St Boniface Hospital) over a 1 year period (1997-98). This period was selected to allow 1) sufficient case numbers 2) a wish to select recent cases to ensure ease of retrieval of relatively recent blocks/cases balanced against 3) a wish to ensure that it was unlikely that there were clinical priorities which might necessitate a review of paraffin blocks from any of the cases. This query yielded 149 invasive tumors, 42 in-situ carcinomas, 62 cases with ductal or lobular hyperplasia + other fibrocystic changes, 43 cases with other benign lesions only

including 4 papillomas, 12 fat necrosis, and 43 fibroadenomas, and 59 cases with no reported pathology (examples shown in sheets 'invasive for review', 'in-situ', 'DH,LH,+FCC'). See **appendix 1.**

2. To construct first a series of cases for study comprising normal, benign, proliferative, or insitu carcinma lesions matched to a synchronous invasive carcinoma in the same patient we have completed a detailed review of all slides from all 149 invasive carcinoma cases. The results are detailed in the attached spreadsheet (invasive reviewed sheet, see **appendix 1**). Specific blocks containing each pathology have now been selected from each case as noted in the appropriate columns (note that the block nomenclature/details vary by individual pathologists practice). The columns are as follows; patient# (MBED patient#), lab# (hospital path lab #), age, agePM (age >=55), invasive, inv+is, is, adh, dh, fcc, n, node met (blocks containing invasive tumor, in-situ components within invasive tumor, in-situ beyond invasive tumor margin, atypical and typical ductal hyperplasia, fibrocystic changes including adenosis and apocrine metaplasia, normal ducts/lobules, nodal metastasis). Invasive tumor type, surgery date, operation type (codes provided in spreadsheet 'MBED codes'). From the initial 149 cases, 79 post-menopausal (>55yrs) cases emerged with invasive tumor and including matching DCIS separate from the invasive tumor in 19 cases, ADH in 10 cases, TDH in 24 cases for example.

We anticipate obtaining a similar number of cases from either the second hospital center and/or extension and review of a more recent second period of 1998-1999 cases from St Boniface hospital.

- 3. Development and pilot testing of the appropriate controls are in progress. Initially we were to select tumors from the Manitoba Breast Tumorbank representative of negative, low and high levels of appropriate gene expression to use as controls. Since then an additional method has been published documenting the use of cultured cells embedded in agar as a control for quantitative immunohistochemical analysis of estrogen receptor in breast cancer (13). Therefore we are in the process of pilot testing this as an additional control in our study, as well as a control for our *in situ* hydridization analyses.
- 4. Preliminary studies to determine if certain estrogen receptor cofactors (6), which could modulate ER transcriptional activity, are altered in expression during breast tumorigenesis and/or breast cancer progression *in vivo* have either been completed {SRA, REA, (9, 10) or are in progress (AlB1 (7) p68 helicase (14)}.

We have examined the expression of a novel recently described steroid receptor RNA activator (SRA) in human breast tissues. Initially the expression of SRA was measured by semi-quantitative reverse-transcription polymerase chain reaction within 27 independent breast tumors, spanning a wide spectrum of grade, estrogen receptor (ER) and progesterone receptor (PR) levels. Subgroup analysis showed that SRA expression was similar in ER+/PR+ (median = 65.5, n = 8) and in ER-/PR- (median = 94.6, n = 5) tumors. Interestingly, SRA expression in these two subgroups was significantly (Mann-Whitney rank-sum test, p < 0.05) lower than that observed in ER+/PR- (median = 156.4, n = 6) and ER-/PR+ (median = 144.8, n = 8) tumors. A variant form of SRA, presenting a deletion of 203 bp within the SRA core sequence, was also observed in breast tumor tissues. The relative expression of this new SRA isoform correlated with tumor grade (Spearman coefficent r = 0.53, n = 27, p = 0.004). These data suggest that changes in the expression of SRA related molecules occur during breast tumor progression (15). These data are now published (see **appendix 2**).

As well, using reverse transcription polymerase chain reaction assays, expression of SRA was compared between adjacent normal human breast tissue and matched breast tumors from 19 patients. Core SRA RNA was detected in normal and neoplastic breast tissues. The level of SRA RNA was significantly (Wilcoxon test, p = 0.0004) higher in breast tumors than in matched normal breast. A deleted SRA RNA was detected in most samples of normal breast and tumors. No differences occurred in the relative expression of the deleted SRA between normal breast and tumors. Within the breast tumor cohort the relative expression of the deleted SRA was positively correlated with tumor grade (Spearman r = 0.556, p = 0.0135) and size (Spearman r = 0.655, p = 0.0023). These data suggest that expression of core SRA is upregulated during breast tumorigenesis and that changes in the relative expression of a deleted SRA isoform occur during breast cancer progression. These data have been submitted for publication (16) see **appendix 3**).

Recently, a repressor of estrogen receptor activity (REA) also known as BAP37 was identified as a repressor of ER (10). It was relevant therefore to determine if REA was expressed in breast tissue and if so was its expression altered during tumorigenesis. We measured REA mRNA levels in normal and neoplastic human breast tissues. A single ~1.7 kb REA mRNA was identified by Northern blotting in breast cancer cells and biopsies. REA mRNA was measured by RT-PCR in ER+ breast tumors and matched adjacent normal tissue. Some breast tumors (12/19) contained higher levels of REA mRNA than their normal tissues,

but this was not statistical significant, although as shown previously *SRA* RNA, an ER coactivator, was significantly increased in tumors versus matched normal tissue in this set (16). REA mRNA levels varied amongst tumors and were found to be positively correlated (Spearman r=0.323, p=0.042) with ER level (determined by ligand binding) and inversely correlated with grade (Spearman r=-0.438, p = 0.0054). However, estrogen did not regulate REA mRNA steady state levels in MCF7 cells and progestins did not regulate REA mRNA steady state levels in T-47D human breast cancer cells in culture. These data suggest that while REA expression may not be altered in early breast tumorigenesis, altered regulation may contribute to breast cancer progression. These data are being written up in a manuscript and have been submitted to AACR in abstract form (17), see **appendix 4**).

These data suggest that alteration of factors, which can modulate ER signal transduction, occur during breast tumorigenesis and provide a very strong rationale to determine in parallel their expression during the early stages of pre-neoplastic progression that precede the onset of invasive breast cancer and determine if differences exist between normal women and patients who develop breast cancer, in order to assess a potential role in increasing the risk of invasive breast cancer. See attached published article and submitted manuscript and abstracts, in **appendices 2, 3 and 4**.

7. KEY RESEARCH ACCOMPLISHMENTS.

- * identification of initial patient cohort for study.
- * retrieval, review and collection of appropriate tissues blocks for analyses.
- * analysis of SRA expression in human breast tissues showing that SRA expression is increased during human breast tumorigenesis.
- * analysis of SRA expression in human breast tumors showing that SRA-like expression varies amongst human breast tumors and may be altered during breast cancer progression.
- *analysis of REA expression in human breast tissues showing that little alteration of REA expression occurs during breast tumorigenesis but its expression in breast tumors correlates with markers of good prognosis i.e. estrogen receptor expression and low grade.

8. REPORTABLE OUTCOMES.

1. Leygue E, Dotzlaw H, Watson PH, Murphy LC (1999) Expression of the steroid receptor RNA activator (SRA) in human breast tumors. Cancer Res 59: 4190-4193. See appendix 2

- 2. Leygue E, Dotzlaw H, Simon SR, Watson PH, Murphy LC (submitted)
 Increased expression of the steroid receptor RNA activator (SRA) during human breast tumorigenesis. See appendix 3
- 3. Simons SLR, Parkes A, Leygue E, Dotzlaw H, Watson PH, Murphy LC (submitted) Expression of a repressor of estrogen receptor (ER) activity (REA) in human breast tissues. 91st Annual Meeting of the AACR, San Francisco, CA,

April 1-5, 2000. See appendix 4

9. CONCLUSIONS.

Our previous results together with our current results suggest that estrogen receptor mediated signal transduction is complex and multifaceted in human breast cancer. Our previous data suggested that altered expression of estrogen receptor- α , estrogen receptor- β and their variants occurs during breast tumorigenesis. Our current data suggest that expression of cofactors which enhance estrogen receptor activity, e.g. SRA, is increased during breast tumorigenesis while expression of cofactors which can repress estrogen receptor activity, e.g. REA, either does not change or is not increased to a similar extent during breast tumorigenesis. Overall the data support the hypothesis that a substantial alteration of estrogen signaling pathways occurs during human breast tumorigenesis. In addition both our previous and our current data provide a very strong rationale to determine in parallel estrogen receptor isoform/variant expression and cofactor expression during the early stages of pre-neoplastic progression that precede the onset of invasive breast cancer and determine if differences exist between normal women and patients who develop breast cancer, in order to assess a potential role in increasing the risk of invasive breast cancer.

8. REFERENCES:

- 1. E. Leygue, L. Murphy, F. Kuttenn, P. Watson, Am J Pathol 148, 1097-1103 (1996).
- 2. E. R. Leygue, P. H. Watson, L. C. Murphy, J Natl Cancer Inst 88, 284-290 (1996).
- 3. E. Leygue, H. Dotzlaw, P. Watson, L. Murphy, *Cancer Res* **58**, 3197-3201 (1998).
- 4. B. Shoker, C. Jarvis, D. Sibson, C. Walker, J. Sloane, *J Pathol* **188**, 237-244. (1999).
- 5. I. Erenburg, B. Schachter, R. M. y. Lopez, L. Ossowski, *Mol Endocrinol* 11, 2004-2015 (1997).
- 6. N. McKenna, R. Lanz, B. O'Malley, *Endocrine Rev* **20**, 321-344 (1999).
- 7. S. Anzick, et al., *Science* **277**, 965-968 (1997).
- 8. S. Bautista, et al., Clin Cancer Res 4, 2925-2929. (1998).
- 9. R. Lanz, et al., Cell 97, 17-27. (1999).

- 10. M. Montano, et al., *Proc Natl Acad Scie USA* **96**, 6947-6952 (1999).
- 11. R. Zwijsen, et al., Cell 88, 405-415 (1997).
- 12. S. Kato, et al., *Science* **270**, 1491-1494 (1995).
- 13. J. Riera, J. Simpson, R. Tamayo, H. B. ., Am J Clin Pathol 111, 329-335. (1999).
- 14. H. Endoh, et al., *Mol Cell Biol* **19**, 5363-5372. (1999).
- 15. E. Leygue, H. Dotzlaw, P. Watson, L. Murphy, *Cancer Res* **59**, 4190-4193 (1999). **Appendix 2.**
- 16. E. Leygue, H. Dotzlaw, S. Simon, P. Watson, L. Murphy, (submitted). Appendix 3.
- 17. S. Simons, et al., AACR 91st Annual Meeting, San Francisco, CA (2000 (submitted)). Appendix 4.

APPENDIX 1

240 07-4450 0	28.7	7		2		T A MICAL DE	3	
A 57 07848 6			L					2
659 97s2822-2		¥	A				C.E	
749 9787771-4	75	i e	: 4					ව
967 9784721-8	81	A			The second secon			many in the second control of the second con
1821 9788758-4	81	A			advanta e constante considerate and a second			
1998 97s8743-6	61	A	K		And the state of t			
2686 98-s769-8	99	A	=	G,C,F,K,J			10 Table 10	Ğ
2439 98-s2875-8	62	A,A		A CONTRACTOR OF THE CONTRACTOR			H1,G	
2439 97-s10898-4	62	A,B1					B4,E	
1502 97s7008-5	57	A,F	F,A				ပ	
1919 97s8756-0	64	A,G2	G2					
642 97s127-6	92	¥	A5	CO	The state of the s	A4,A5		
1436 97s6303-6	28	A1	A1		A1	A1,B1	6	
1843 97 s 8 6 9 2 - 3	57	A1	A1				B2	
2045 9789417-9	92	A1				ខ		
2621 97-s12739-6	64	A1					A1	A6
2624 97-s12732-7	73	A1	A5		A5	A1,A6-2	83	
451 97s125-2	88	A1,A3	A5			A3,A5	a	
1443 97s6282-2	89	A1-1	A1	B2, A3-2	B2,A3-2		A6	A3
2055 97s9298-8	78	A2			A2,B			0
393 97s1393-8	63	A3	A3					A5
3210 98-3982	80	A3		200				.
2468 97-s11703-8	84	A3,A2		a,b	۵	O	ပ	
1096 97s5059-3	29	A3,A5			DŞ	A3,D2,D4		
724 97 s1400-1	99	44	*					A12
538 97s7560-2	02	44		A5-1				
510 97s1601-0	29	A5		В,Г		A5		
1442 97s6325-6	26	A5	A 5				A 4	*
3562 98-5401	29	A5	A1					4 4
2861 98-s1678-0	99	Ą		Ą				
2909 98-5417	63	AA		B11				B11
1028 97s4591-7	91	œ	m			m		6
1546 97s7476-6	72	ന	Δ					
716 97s 8209-1	69	m						
2438 97-s11006-2		Δ	m					
1898 97s8657-6	19	82	11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			_		
896 97s3756-5	24	B3,C3	83,C3	DX2				Ω
2613 97-s11715-5	88	8 4		The state of the s		\$		Ž
1555 97s7679-9	72	87		3		85		
1822 97s8690-9	29	ပ	And the second for the second	11.0		,		
556 97s7633-5	72	ឌ	ឌ					
392 97s1594-7	8	3						
3145 98-s2714-2	65	۵	C1,C2	E3,E4		E1,C1,C2	2	
1435 97s6619-4	73	D,E	0		ш			The state of the s
496 97s1855-5	28	DCIS		A,D				a
203 97\$2848-0	99		9	THE PARTY OF THE P	And the state of t			Z
2462 97-s12384-2		Ш				H1,G6	H2,G7	2
2656 97-s11708-3	56	E1.E3	7.4	- I - III - IIII - IIIII - IIII - III			ī	α
							-	

NODE MET	invasive	surgery-date	peration-type1
			8543
	D-INF	18-Feb-97	8521
	D-INF	17-Mar-97	8521
	D-INF	29-Jul-97	8512
	D-INF	8-May-97	8543
	D-INF	2-Sep-97	8512
	T-INF	2-Sep-97	8521
	D-INF	23-Jan-98	8543
***************************************	L-INF	24-Mar-98	8521
	D-INF+T-INF	28-Oct-97	8512
13	D-INF	7-Jul-97	8512
	D-INF	2-Sep-97	8521
	D-INF+COL-INF	6-Jan-97	8512
		17-Jun-97	8521
Tanquarian at atangapapagan amada	D-INF	29-Aug-97	8521
D2	D-INF	19-Sep-97	8521
	T-INF	15-Dec-97	8512
	D-INF	15-Dec-97	8521
	D-INF	6-Jan-97	8541
	D-INF	17-Jun-97	8521
	COL-INF	16-Sep-97	8521
	D-INF	6-Feb-97	8521
	D-INF	28-Apr-98	8521
	D-INF	18-Nov-97	8543
D7-1,D7-3	D-INF	20-May-97	8512
	P.I.P.	6-Feb-97	8543
	LP	22-Jul-97	8512
G3	D-INF	12-Feb-97	8521
	D-INF	17-Jun-97	8521
	D-INF	9-Jun-98	8543
J. Y.	D-INF	17-Feb-98	8521
	D-INF	9-Jun-98	8512
	D-INF	5-May-97	8521
H17	P.N.	21-Jul-97	8521
m	L	14-Aug-97	8512
	D-!NF	30-Oct-97	8521
	PN-	29-Aug-97	8521
=	D-INF	15-Apr-97	8521
	L-INF	19-Nov-97	8512
- 4	10-2	/6-Inr-cz	8521
	- NI-O	78-BNY-87	7100
		24-Jul-97	8521
The Tendon	Ę	12-rep-9/	8543
£	O-IN-	19-Mar-98	8512
	D-INF	24-Jun-97	8521
	D-INF	18-Feb-97	8512
	N-01	17-Mar-97	8543
	IV-OT	5-Dec-97	8521
	D-INF	19-Nov-97	8523
10.0	D-INF	16-Dec-97	8521

1434 9786611-8	3	#1-3,D	2,2			C	V 1000	
209 97\$1443-4	/4	E14		Commence of the commence of th	***************************************	·	۵	
243/97-\$10625-0	69	E3,A5	E2,D4		0,000		Cropping and a second a second and a second	4
299 97s1234-6	59	E7	E 7				E 7	
2627 97-s11411-4	56	F1,G1	F1,G1		63,11	K,H,D2,C3,E3	D2,E2	
1437 97s6639-0	72	F5	A5			Ā		
2600 97-s11870-9	7	G						
1463 97s6381-6 1	58	I				_	¥	-
2634 97-s11381-4	72	K,Ľ,⊠					FS1	ائو
602 97s2342-3	80	_		9		C2,C5	C2,C5	7
2631 97-s11398-6	84	Ω, Ω	C,E				Z	
203 97s1728-6 1	99	PN		The same of the sa		The state of the s		
2637 98-s427-9	57	PZ		The state of the s		The state of the s		The state of the s
3110 98-s1795-6	72	PN	- delignon and more delignon and and			The second secon		
3155 98-s2757-5	83	PN						
2986 98-s1675-9	87	PNX2						
2098 97 s 97 28-2	82	13	The second secon	a		ī		
298 97s1250-4	25		٥	4			a	<
389 97s1434-8	75		¥					a
512 97s898-1	74		and a second sec					
694 96s13076-7	99							
724 97s1121-1	- IC							
806 07e4623- 4	74						ΔA	
067 07e4243 -1	δ							
1053 97s4892-7	85							
1053 9787980-2	258							
143 97 5 186-2	92						***************************************	
186 97 5 5 35 - 6	28							
454 97s6510-0	64							
1953 97-s10478-4	89		B 2			ខ		B4
2107 97s9566-8	48							
2453 97-s10695- 1	63		-					
2602 97-s12170-9	4							
2602 97-s12469-2	77		THE THE PARTY WHEN THE PARTY WHEN THE PARTY WAS A PARTY WHEN THE PARTY WAS A P					
2624 97-s11336-4	73				a management of the second			
2635 97-s11112-8	09		E1,E2					G2
2685 98-s361-8	72		ပ	ပ				
2695 98-s963-8	62							
2858 98-s1701-1	95		A	A2,A3,B				Φ.
3027 98-s653-2	89		1	10(LCIS)		•	The state of the s	9
3028 98-s523-2	73		A,K	J,L,M	***************************************	G,P7		The state of the s
3146 98-52849-7	<u> </u>		B2				of a second description of a second s	D3
3212 98- s 3033-1	74		A,B,D,E					
3271 98-\$3319-0	99	a badhadanthantan of there is		Company of the contract of the	s season of the first business and delegate before	andralla deliberaturella in terrenterare en escado del esta	The second secon	The state of the s
3538 98-5152	1		B4,A2-1	B2,A1	8 4	A2-3	A4-3	4
3655 98-5192	73	Andrew Company of the	Cardologo general and an annual and an	The same of the sa				
3655 98-6408	73	natural statement of the statement of th	11110 H. 1110	Water the same of	W	The same of the first from the same of the	The state of the s	The second secon
3676 98-5447	73		· · · · · · · · · · · · · · · · · · ·	The second secon	and a second second second second second			
3754 98-6194	99	and have the control of the control of the con-	V	- Comments		THE THE PERSON OF THE PERSON O		The second secon
2700 00 5415						annon management	***************************************	
C4.C-X	2							

8521	8521	8521	8512	8512	8521	8512	8521	8521	8512	8512	8512	344	8512	1268	8521	344	8512	8512	8541	8512	8512	9542	8512	8521	8543	8512	8512	8543	8512	8521	8543	8521	8512	8521	8543	8512	8512	8521	8512	8521	8512	8521	7168
24-Jun-97 7-Fah-97	21-Oct-97	3-Feb-97	10-Nov-97	24-Jun-97	24-Nov-97	19-Jun-97	10-Nov-97 3 Mar-07	10-Nov-97	14-Feb-97	14-Jan-98	19-Feb-98	20-Mar-98	17-Feb-98	76-Sep-97	3-Feb-97	/-reb-9/ 24-lan-97	6-Dec-96	30-Jan-97	6-May-97	25-Apr-97	14-May-97	22 May 97	4-Jun-97	20-Jun-97	16-Oct-97	23-Sep-97	1-Dec-97	8-Dec-97	7-Nov-97	3-Nov-97	13-Jan-98	40-Jail-90	20-Jan-98	16-Jan-98	24-Mar-98	30-Mar-98	8-Apr-98	1-Jun-98	2-Jun-98	10-Jul-98	10-Jun-98	30-Jun-98	96-Unr-1.
D-INT	-INF	LINE	D-INF	D-INF	D-INF	D-INF	D-INF		IV-OŢ	D-INF	D-INF	Z.			7N-0		N-O1	D-INF	D-INF	D-INF	_ 		D-INF	D-INF	P-INF	L-INF	D-INF	D-INF	D-INF	D-INF	-N-C	D-INF+COL-INF	L-INF	D-INF	D-INF	D-INF+T-INF	<u> </u>	COL-INF	Z-IN-	LINE	COL-INF	D-INF	TNI-1
				1				4																																			

3888 98-6153 3869 98-5805 3364 98-5305 515 97-511579-9 515 97-51790-1 3073 98-5233-4 3111 98-5133-6 684 97-539-6 599 97-555-1 2095 97-59149-9 1468 97-5655-8 1501 97-5655-8 1501 97-598-6 1501 97-508-6 1604 97-5918-6 1604 97-5918-6 1604 97-5918-6 1705 97-5898-6 1706 97-5898-6 1707 97-5918-6 1708 97-508-6 1708 97-508-6 1708 97-508-6 1709 97-508	65 65 1 1 1 4 4 4 1,2 4 5 A 4 7 A,B 5 2 A2 5 2 A2 5 2 A2 5 3 A5 5 4 0 6 4 9 B,A 6 6 8 B,B 6 7 C 7 C 8 1 B,B 6 8 B,B 6 7 C 7 C 7 C 8 1 B,B 6 1 C 7 C 7 C 8 1 B,B 8 1 C 7 C 8 1 B,B 8 1 C 8 1 C 8 1 C 8 1 C 8 2 C 8 3 3 9 B,A 8 1 C 8 1 C 8 1 C 8 2 C 8 2 C 8 3 3 9 B,A 8 1 C 8 1 C 8 2 C 8 3 3 9 B,B 8 6 C 8 7 C 8 7 C 8 8 1 C 8 7 C 8 8 1 C 8 8 1 C 8 8 1 C 8 8 2 C 8 8 2 C 8 8 2 C 8 8 3 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	7,7 A1,A3 A1,A3 A6 B3,C2 C C C;	A4, B2	<u>P2</u>		
		7,2 A1,A3 A1,A3 B3,C2 C C C7	A4,B2	F		2
		7,2 A1,A3 A4 A5 B3,C2 C C C7	A4,B2	B		9
		71,2 A1,A3 A1,A4 A5 B3,C2 C C C7	A4,B2	F2)
		A1,A3 A1,A3 B3,C2 C C C7	A4,B2	2		~
		A1,A3 A4 A5 B3,C2 C C C7	A4,B2		17.7	F
		A1,A3 A1,A3 B3,C2 C C C7	A4,B2	A COLUMN TO THE TAXABLE TO THE TAXAB		
		A1,A3 A1 A5 B3,C2 C C C7	A4,82		The state of the s	
		A1,A3 A1 A6 B3,C2 C C C7	A4,B2	Annual Junior Junior State of the State of t		
		A1,A3 A4 A5 B3,C2 C C C7	A4,B2		4	ă
		A1,A3 A1 A5 B3,C2 C7 C7	A4,B2		8	¥
		A1,A3 A1 A5 B3,C2 C C C7	А4,82			ភ
		A1 A5 B3,C2 B4,B5,B3 C C	A4,B2		A6,A7,B	0
		A1 A5 B3,C2 C C C7			a comment of the comm	A18
		A6 B3,C2 C C C7 D3		D2	D1,A2	
		B3,C2 B4,B5,B3 C C7 D3			A6	
		B3,C2 B4,B5,B3 C C7 D3				
		B4, B5, B3 C C C77				2
		B4, B5, B3 C C7 D3			ī	
		C7 C7 D3				2
2 5		C	54,5,5			5 (
0		C7	ı			ָ פי י
0		ර <u>්</u>				2
0		D 3				
0		23		B3,A,C	,C B1,B5	ν V
0			D3	J.Y.		
0	:			X	ပ	<u>.</u>
the same of the sa	45 FS2,A1-6	FS2			The state of the s	Ā
•		S	95	G(other)		۵
	37 G2					٥
	. —.					_
1176 97s5376-1	52 PHYLOIDES					
	36		VI SURVINI DEPOSIT DE LA CONTRACTOR DE L			
6	36		***************************************			
	46				The second control of	
7	36			The state of the s		
2	42				The second secon	
	52	manuf garagement of the same same same same same same same sam			The state of the s	
2467 97-y6988-1	51					
9	41				The same of the sa	<u></u>
	50	m	The second secon	K5	K3,C,L	-
William Control of the Control of th	36		· · · · · · · · · · · · · · · · · · ·	Annahaman Annahaman - agam	The state of the s	
	54					
Neumannia de de la compositione de	9P					
The state of the s	36	The state of the s	. A Springer of the second sec	Married State of the Control of the	A TO	
	70					
A A A A A A A A A A A A A A A A A A A	4×	Parabantan management		et a september a s	the same approximation of the same state of the	
AND	46				Tryanganing and a make NA NAMA	
3902 98-5710	40	Annual contraction of consecution of the	And the Company of th	a sugar and any any and any	A THE THE PERSON NAMED AND ADDRESS OF THE PERSON NAMED ADDRESS OF THE PERSON NAMED AND ADDRESS OF THE PERSON NAMED ADDRESS OF THE PERSON NAMED ADDRESS OF THE PERSON NAMED ADDRESS OF THE PERS	manufungungung.

	4-May-98 26-Jun-98
COLINF C	D-INF D-INF

Tub

APPENDIX 2

Expression of the Steroid Receptor RNA Activator in Human Breast Tumors¹

Etienne Leygue,² Helmut Dotzlaw, Peter H. Watson, and Leigh C. Murphy

Departments of Biochemistry and Molecular Biology [E. L., H. D., L. C. M.] and Pathology [P. H. W.], University of Manitoba, Faculty of Medicine, Winnipeg, Manitoba, R3E OW3, Canada

Abstract

The expression of the recently described steroid receptor RNA activator (SRA) was measured by semiquantitative reverse transcription-PCR within 27 independent breast tumors, spanning a wide spectrum of grade and estrogen receptor (ER) and progesterone receptor (PR) levels. Subgroup analysis showed that SRA expression was similar in ER+/PR+ (median = 65.5, n = 8) and in ER-/PR- (median = 94.6, n = 5) tumors. Interestingly, SRA expression in these two subgroups was significantly (Mann-Whitney rank-sum test, P < 0.05) lower than that observed in ER+/PR- (median = 156.4, n = 6) and ER-/PR+ (median = 144.8, n = 8) tumors. A variant form of SRA, presenting a deletion of 203 bp within the SRA core sequence, was also observed in breast tumor tissues. The relative expression of this new SRA isoform correlated with tumor grade (Spearman coefficient r = 0.53, n = 27, P = 0.004). These data suggest that changes in the expression of SRA-related molecules occur during breast tumor progression.

Introduction

Estrogens, through their mitogenic action on breast epithelial cells, regulate the growth and the development of normal as well as neoplastic human mammary tissue (1). The ability of antiestrogens such tamoxifen or raloxifene to antagonize this estrogenic action provides the basic rationale for endocrine therapy and prevention (for review see Ref. 2). Estrogen action is mainly mediated through two ERs,³ ER- α and ER- β (3-5), which belong to the steroid/thyroid/retinoic acid receptors superfamily (6) and act as ligand-dependent transcription factors. The mechanisms by which steroid receptors modulate the transcription of target genes is under extensive investigation (7). Once bound to the ligand, the receptors undergo conformational changes and dimers of receptors recognize specific regulatory DNA sequences upstream of target genes. Activated receptors, through interactions with coactivator proteins, direct the assembly and the stabilization of a preinitiation complex that will ultimately conduct the transcription of these genes (see Ref. 8 and references therein). To an already long list of nuclear receptor coactivators (8), which includes the p160 proteins (such as SRC-1 and AIB1), Lanz et al. (9) recently added the SRA. SRA differs from other coactivators in two main ways. (a) SRA transcripts do not appear to be translated, and therefore, this coactivator acts as an RNA and not as a protein. Lanz et al. (9) showed that SRA exists in a ribonucleoprotein complex that contains SRC-1 and is

recruited by steroid receptors. (b) SRA appears to be actually specific for steroid receptors. Indeed, most of the receptor-interacting factors, such as SRC-1 or TIF2/hSRC-2, interact with and coactivate both class I and class II nuclear receptors (9). Because of the importance of ER signaling pathways in the mechanisms underlying breast tumor progression, it was important to establish whether SRA could be expressed in breast tumors. If so, it was also of interest to determine whether the expression of SRA was related to known markers of endocrine sensitivity and prognostic markers. We have selected a subset of breast cancer cases to look for possible correlations between SRA expression and already established predictive and/or prognostic factors, such as grade, ER, and PR status (10).

Materials and Methods

Human Breast Tumors. Twenty-seven cases were selected from the National Cancer Institute of Canada-Manitoba Breast Tumor Bank (Winnipeg, Manitoba, Canada). The cases were selected according to their ER and PR status, as determined by ligand binding assay. Tumors were classified as ER-/PR+(n=8;ER range,5-9 fmol/mg protein;PR range,51-271 fmol/mg protein), ER+/PR-(n=6;ER range,59-151 fmol/mg protein;PR range,5-10 fmol/mg protein), ER-/PR-(n=5;ER range,0-2 fmol/mg protein;PR range,0-8 fmol/mg protein), and <math>ER+/PR+(n=8;ER range,50-127 fmol/mg protein;PR range,101-285 fmol/mg protein). These tumors covered a wide spectrum of grade (grades 4-9), determined using the Nottingham grading system (11). Patients were 49-87 years old.

RNA Extraction and RT-PCR. Total RNA was extracted from frozen breast tissue sections using Trizol reagent (Life Technologies, Inc., Grand Island, NY) according to the manufacturer's instructions and quantified spectrophotometrically. One μ g of total RNA was reverse-transcribed in a final volume of 25 μ l, as described previously (12).

Primers and PCR Conditions. The primers used consisted of SRAcoreU primer (sense, 5'-AGGAACGCGGCTGGAACGA-3', positions 35-53; Gen-Bank accession no. AF092038) and SRA core L primer (antisense, 5'-AGTCT-GGGGAACCGAGGAT-3', positions 696-678; GenBank accession no. AF092038). PCR amplifications were performed and PCR products analyzed as described previously (12), with minor modifications. Briefly, 1 µl of reverse transcription mixture was amplified in a final volume of 15 μ l, in the presence of 1.5 μ Ci of $[\alpha^{-32}P]dCTP$ (3000 Ci/mmol), 4 ng/ μ l each primer, and 0.3 unit of Taq DNA polymerase (Life Technologies, Inc.). Each PCR consisted of 30 cycles (30 s at 60°C, 30 s at 72°C, and 30 s at 94°C). PCR products were then separated on 6% polyacrylamide gels containing 7 м urea. Following electrophoresis, the gels were dried and exposed for 1 h to a Molecular Imager-FX Imaging screen (Bio-Rad, Hercules, CA). Amplification of the ubiquitously expressed GAPDH cDNA was performed in parallel and PCR products separated on agarose gels stained with ethidium bromide as described previously (12). Identity of PCR products was confirmed by subcloning and sequencing, as reported previously (13).

Quantification of SRA Expression. Exposed screens were scanned using a Molecular Imager-FX (Bio-Rad), and the intensity of the SRA corresponding signal was measured using Quantity One software (Bio-Rad). Three independent PCRs were performed. To control for variations between experiments, a value of 100% was arbitrarily assigned to the SRA signal of one particular tumor (tumor 14) measured in each set of PCR experiments, and all signals were expressed as a percentage of this signal. In parallel, GAPDH cDNA was amplified and following analysis of PCR products on prestained agarose gels, signals were quantified by scanning using NIH Image 161/ppc software. Three

Received 6/16/99; accepted 7/20/99.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by grants from the Canadian Breast Cancer Research Initiative and the United States Army Medical Research and Materiel Command. The Manitoba Breast Tumor Bank is supported by funding from the National Cancer Institute of Canada. P. H. W. is a Medical Research Council of Canada Scientist, L. C. M. is a Medical Research Council of Canada Scientist, and E. L. is a recipient of a United States Army Medical Research and Materiel Command Postdoctoral Fellowship.

² To whom requests for reprints should be addressed, at Department of Biochemistry and Molecular Biology, University of Manitoba, Winnipeg, Manitoba R3E OW3, Canada. Phone: (204) 789-3812; Fax: (204) 789-3900; E-mail: eleygue@cc.umanitoba.ca.

³ The abbreviations used are: ER, estrogen receptor; SRA, steroid receptor RNA activator; PR, progesterone receptor; RT-PCR, reverse transcriptase-PCR; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.




Fig. 1. SRA structure and primer presentation. SRA isoforms identified to date (9) differ their 5' and 3' terminal regions (■) but present an identical nucleotide sequence (□) in Detween (SRA core sequence, bases 28 to 720). SRAcoreU and SRAcoreL primers anneal with SRA core sequences and allow the amplification of a 662-bp fragment.

independent PCRs were performed. Each GAPDH signal was also expressed as a percentage of the signal observed in the tumor 14. For each sample, the average of SRA signal was then expressed as a percentage of the GAPDH signal (arbitrary units).

Quantification of SRA-Del Relative Expression. It has previously been frown that the coamplification of a wild-type and a deleted variant cDNA resulted in the amplification of two PCR products, the relative signal intensity of which provided a reliable measurement of the relative expression of the deleted variant (13, 14). For each sample, SRA-Del corresponding signal was measured using Quantity One software (Bio-Rad) and expressed as a percentage of the corresponding SRA signal. For each case, three independent assays were performed, and the mean was determined.

Statistical Analysis. Differences between tumor subgroups were tested using the two-sided Mann-Whitney rank sum test. Correlation between SRA expression and tumor characteristics was tested by calculation of the Spearman coefficient r.

Results

Detection of SRA and a Variant mRNA Deleted Form (SRA-Del) in Human Breast Tumor Tissues. The existence of three different SRA mRNAs have been reported (9). The sequences of these isoforms differ in their 5'- and 3'-terminal regions but are identical within their central region, called the core (Fig. 1). To investigate the expression of all described SRA isoforms in human breast tumor tissues, we designed primers to amplify a 662-bp fragment encompassing almost all of the SRA core region. Total RNA was extracted .rom 27 human breast tumors and reverse-transcribed, and PCR amplification was performed as described in the "Materials and Methods" using SRA core primers. A 662-bp fragment was obtained in all samples. However, the intensity levels varied from one sample to another (Fig. 2A). This fragment was sequenced and corresponded to the SRA core region. The differences in SRA expression were unlikely to result from different cDNA input, as shown by the similar intensities of GAPDH signal obtained after amplifying GAPDH mRNA in parallel using the same cDNAs (Fig. 2B). An additional fragment, migrating at an apparent size of 459 bp was also observed in most samples. Sequencing analysis revealed that this band corresponded to a variant form of SRA (referred to as SRA-Del) deleted in 203 bp between positions 155 and 357 (corresponding to GenBank accession no. AF092038).

The Expression of SRA Correlates with ER and PR Levels in Subgroups of Human Breast Tumors. For each case, the SRA-corresponding signal was quantified and expressed in arbitrary units, as described in "Materials and Methods." Results obtained from the 27 cases, grouped according to their ER and PR levels, as determined by ligand binding analysis, are presented Fig. 3A. When the cohort of cases was considered as a whole (n = 27), no correlation was observed between SRA expression and ER or PR levels. Indeed, similar levels of SRA were found in ER+/PR+ (median = 65.5, n = 8) and ER-/PR- (median = 94.6, n = 5) tumors (Fig. 3A). However, when only ER- tumors were considered (n = 13), a trend toward a positive correlation between SRA expression and PR levels was observed (Spearman coefficient r = 0.527, P = 0.064). SRA expression was higher in ER-/PR+ (n = 8, median = 144.8) than it

was in ER-/PR- tumors (Fig. 3A); this difference was statistically significant (two-sided Mann-Whitney rank sum test, P=0.045). In contrast, within ER+ cases (n=14), SRA expression negatively correlated with PR levels (Spearman coefficient r=-0.810, P=0.0004). SRA expression was higher (two-sided Mann-Whitney rank sum test, P=0.001) in ER+/PR- (n=6, median = 156.4) than it was in ER+/PR+ cases. In a similar way, SRA expression correlated positively (Spearman coefficient r=0.735, P=0.009) and negatively (Spearman coefficient r=-0.532, P=0.033) with ER levels in PR- (n=11) and PR+ (n=16) cases, respectively. SRA levels were higher in ER+/PR- than in ER-/PR- tumors (two-sided Mann-Whitney rank sum test, P=0.017) and in ER-/PR+ than in ER+/PR+ cases (two-sided Mann-Whitney rank sum test, P=0.047). SRA levels of expression did not correlate with tumor grade scores (Fig. 3B).

The Expression of SRA-Del Correlates with Breast Tumor Grade Scores. For each case, SRA-Del signal was measured and expressed relative to the corresponding SRA signal, as described in the "Materials and Methods." SRA-Del relative signal did not correlate with ER or PR levels when the cohort of cases was considered as a whole or when ER-, ER+, and PR- subgroups were analyzed. Interestingly, SRA-Del expression positively correlated (Spearman coefficient r = 0.512, P = 0.042) with PR levels in PR+ subgroup (n = 16). However, no statistically significant differences (Fig. 4A) were observed between ER-/PR+ (n = 8, median = 2.346), ER+/ PR - (n = 6, median = 2.561), ER - /PR - (n = 5, median = 6.571)and ER+/PR+ (n = 8, median = 3.528). By contrast, SRA-Del levels strongly correlated (Spearman coefficient r = 0.530, P = 0.004) with Nottingham grade scores within the whole cohort (n = 27). The level of expression of SRA was significantly higher (two-sided Mann-Whitney rank sum test, P < 0.05) in tumors of high grade (n = 7, median = 6.572) than it was in tumors of low (n = 4, median = 2.192) or intermediate (n = 9, median = 2.588) grade (Fig.

Discussion

Using primers annealing with the core region of the three previously described *SRA* isoforms (9), we have investigated *SRA* expression in 27 independent breast tumors by means of semiquantitative RT-PCR. These *SRA* isoforms, although different in their 5'- and 3'-terminal regions, are all able to coactivate steroid receptor. Indeed,




Fig. 2. Detection of SRA in human breast tumors by RT-PCR. Total RNA was extracted from 27 breast tumors, reverse-transcribed, and analyzed by PCR as described in "Materials and Methods." PCR products were separated on 6% acrylamide gels. Gels were dried and exposed 1 h to a Molecular Imager-FX Imaging screen. Screens were then scanned using a Molecular Imager-FX. A, computerized image showing the results obtained for 13 cases (Lanes 1–13). Lane M, molecular weight marker (φx174 RF DNA/HaeIII fragments). Lane C, control lane, no cDNA added in the PCR. Sequencing analysis of PCR fragments revealed that the 662-bp (SRA) and 459-bp (SRA-Del) fragments corresponded to SRA and to a variant SRA isoform deleted in sequences from position 155 to 357 (GenBank accession no. AF092038), respectively. B, ethidium bromide-stained gel of the RT-PCR analysis of GAPDH mRNA run in parallel for the same samples.





Fig. 3. Subgroup analysis of SRA expression within 27 human breast tumors. For each case, SRA expression was quantified and expressed in arbitrary units as described in "Materials and Methods." A, tumors were grouped according to their ER and PR status, as determined by ligand binding assay. □, ER−/PR+ tumors; ●, ER+/PR− tumors; ■, ER−/PR− tumors; and ○, ER+/PR+ tumors. B, tumors were grouped according to their grade: low (Nottingham grading scores 4−5), intermediate (Nottingham grading scores 6−7), and high (Nottingham grading scores 8−9). The horizontal line represents the median value in each group. Ps (two-sided Mann-Whitney rank sum test) are indicated when subgroups were statistically different. ns; no statistically significant differences were found between subgroups.

SRA core region was found to be necessary and sufficient for the coactivation properties of SRA isoforms (9). Therefore, although PCR performed using primers spanning the SRA core region is likely to recognize several different SRA-like molecules, the signal obtained corresponds to molecules that should all have essentially the same function, i.e., coactivation of steroid receptors.

The expression of SRA did not correlate with ER or PR status when the cohort was considered as a whole. This differs from what has been observed for another coactivator, AIB1. Indeed, Anzick et al. (15) first showed that a strong expression of AIB1 that resulted from AIB1 gene amplification was observed in ER+ but not in ER- breast cancer cell lines. More recently, Bautista et al. (16) reported that AIB1 gene amplification correlated with ER and PR positivity. Our results suggest that the pattern of expression of SRA is more complex. Indeed, we found that SRA expression could correlate positively or negatively with ER and PR levels, depending on the subgroup considered. The general trend appeared to be that, in tumors expressing a low level of one receptor (ER or PR), a positive correlation was found between SRA expression and the second receptor (PR or ER). Inversely, in tumors highly expressing one receptor (ER or PR), SRA expression negatively correlated with the level of expression of the second

receptor (PR or ER). At this stage of the knowledge of SRA biological function, the interpretation of such an observation is difficult. Indeed, SRA has been shown to be able to coactivate both ER and PR (9). Moreover, progestins are known to decrease the steady state levels of ER-α mRNA and protein, whereas estrogens increase PR expression (17, 18). Therefore, all combinations and cross-talk appear possible. One could speculate that increased levels of SRA in ER-/PR+ cases could partially be responsible, by "boosting" the activity of the weakly expressed ER, of the expression of PR in these tumors. Inversely, in the same ER-/PR+ cases, the strong SRA expression could be responsible for an increased down-regulation of ER by PR. Our results suggest that SRA expression varies from one particular tumor to another. Changes in SRA expression can be associated with known prognostic and predictive factors such as ER and PR in particular tumor subgroups. The question of a direct involvement of SRA in the hormonal status changes occurring during breast tumor progression remains unanswered. Also of interest is the fact that SRA interacts with the activation function 1 of the steroid receptors (9). Activation function 1 is thought to mediate the agonistic effect of antiestrogens such hydroxytamoxifen (19). This agonistic action of antiestrogens is believed to be involved in part in the mechanisms underlying hormone






Fig. 4. Subgroup analysis of SRA-Del relative expression within 27 human breast tumors. For each case, SRA-D3 expression relative to SRA was quantified as described in "Materials and Methods." A, tumors were grouped according to their ER and PR status, as determined by ligand binding assay. □, ER−/PR+ tumors; ●, ER+/PR− tumors; and ○, ER+/PR+ tumors. B, tumors were grouped according to their grade: low (Nottingham grading scores 4-5), intermediate (Nottingham grading scores 6-7), and high (Nottingham grading scores 8-9). The horizontal line represents the median value in each group. Ps (two-sided Mann-Whitney rank sum test) are indicated when subgroups were statistically different. ns; no statistically significant differences were found between subgroups.

resistance in breast cancer. One could speculate that the level of SRA expression might, therefore, modulate and predict the response of a given tumor to hormone therapy. This hypothesis appears to be refuted by the observation of similar levels of SRA in ER+/PR+ and ER-/PR- tumors. But ER+/PR+ tumors, as opposed to ER-/PRamors, are likely to respond to endocrine therapy and prevention (see Ref. 2 and references therein). In these cases, the differences in ER levels rather than in SRA expression are more likely involved in the mechanisms underlying endocrine sensitivity. On the other hand, the observation of a higher SRA expression within ER-/PR+ cases, which are more likely to respond to hormone therapy than ER-/PRtumors (see Ref. 20 and references therein), would be consistent with the hypothesis of a possible involvement of SRA in these mechanisms under some circumstances. One should also note that Berns et al. (21) recently reported that, although no correlation was found between the expression of SRC-1 and ER status, a high expression of this coactivator indicated a favorable response to tamoxifen of patients with recurrent breast cancer. This issue can only be addressed in studies performed on tumors from patients that did and did not respond to endocrine therapy.

We have identified in breast tumor cases a new SRA isoform deleted in sequences from nucleotide 155 to 357 (SRA-Del). Interestingly, sequence comparison using the BLAST algorithm and the human EST database showed that this deleted SRA isoform has already been found in a pooled cDNA library containing cDNAs from melanocyte, fetal heart, and pregnant uterus (GenBank accession no. AA426601). Because uterus is another steroid target tissue, it could be hypothesized that the source of SRA-Del in this pooled library was, indeed, uterus. Even though the structure of the SRA gene has not yet been published, SRA-Del appears to correspond to a perfect exon-3 deleted SRA variant. SRA gene has recently been located on chromosome 5q31.3-32.4 Sequence analysis of the corresponding DNA sequence (chromosome 5, BAC clone 319C17; GenBank accession no. AC005214) revealed that the fragment from nucleotide 155 to 357 corresponds to the third SRA exon. The putative function of SRA-Del remains to be determined. One should, however, note that a recombinantly developed SRA mutant, deleted of the region 3' of a BbsI site (position 341) and, therefore, partially deleted of exon 3 sequences, did not coactivate steroid receptors (9). Moreover, exon 3 deletion introduces a shift in the open reading frames, suggested by Lanz et al. (9), and could lead to a premature termination of the putative SRA proteins. One could, therefore, hypothesize that SRA-Del might interfere with SRA activity. The resulting modifications of the steroid receptor signaling pathways could confer a more aggressive behavior to the tumors expressing higher levels of SRA-Del. The positive correlation between SRA-Del levels and tumor grade scores would be consistent with this hypothesis.

Interestingly, modifications of the long arm of the chromosome 5 have been reported in breast tumors. Indeed, Hermsen *et al.* (22) found a frequent chromosomal gain in 5q within a subset of 53 lymph node-negative breast carcinoma, whereas Schwendel *et al.* (23) observed a frequent loss of this region in 39 invasive breast carcinomas. Moreover, among *BRCA1* mutation carriers, loss of 5q was observed more frequently than in the control patient (24). One could, therefore, speculate that the loss of *SRA* is selected for during tumor progression in cells lacking *BRCA1* functional gene. Whether changes in *SRA* expression result from chromosomal abnormalities remains to be determined.

In conclusion, we have shown that *SRA* is expressed in breast tumors and that its expression correlates with ER and PR levels in particular tumor subgroups. We speculate that changes in *SRA* expression could be involved in the mechanisms underlying tumor progression and hormone resistance.

References

- Vorherr, H. (ed.). Breast Cancer. Baltimore: Urban and Schwarzenberg Press, 1980.
 Jordan, V. C., and Morrow, M. Tamoxifen, Raloxifene, and the prevention of breast cancer. Endocr. Rev., 20: 253-278, 1999.
- Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J. M., Argos, P., and Chambon, P. Human oestrogen receptor cDNA: sequence, expression and homology to v- erb-A. Nature (Lond.), 320: 134-139, 1986.
- Mosselman, S., Polman, J., and Dijkema, R. ER β: identification and characterization of a novel human estrogen receptor. FEBS Lett., 392: 49-53, 1996.
- Ogawa, S., Inoue, S., Watanabe, T., Hiroi, H., Orimo, A., Hosoi, T., Ouchi, Y., and Muramatsu, M. The complete primary structure of human estrogen receptor β (hER β) and its heterodimerization with ER α in vivo and in vitro. Biochem. Biophys. Res. Commun., 243: 129–132, 1998.
- Evans, R. M. The steroid and thyroid receptor super-family. Science (Washington DC), 240: 889-895, 1988.
- Shibata, H., Spencer, T. E., Onate, S. A., Jenster, G., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Rec. Prog. Horm. Res., 52: 141-164, 1997.
- McKenna, N. J., Lanz, R. B., and O'Malley, B. W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev., 20: 321-344, 1999.
- Lanz, R. B., McKenna, N. J., Onate, S. A., Albrecht, U., Wong, J., Tsai, S. Y., Tsai, M-J., and O'Malley, B. W. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell, 97: 17-27, 1999.
- Henderson, I. C., and Patek, A. J. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res. Treat., 52: 261-288, 1998.
- Elston, C. W., and Ellis, I. O. Pathological prognostic factors in breast cancer. Histopathology, 19: 403-410, 1991.
- Leygue, E., Murphy, L. C., Kuttenn, F., and Watson, P. H. Triple primer PCR: a new way to quantify truncated mRNA expression. Am. J. Pathol., 148: 1097-1103, 1996.
- Leygue, E., Watson, P. H., and Murphy, L. C. Estrogen receptor variants in normal human mammary tissue. J. Natl. Cancer Inst., 88: 284-290, 1996.
- 14. Daffada, A. A. I., Johnston, S. R. D., Nicholls, J., and Dowsett, M. Detection of wild type and exon 5-deleted splice variant oestrogen receptor (ER) mRNA in ER-positive and -negative breast cancer cell lines by reverse transcription/polymerase chain reaction. J. Mol. Endocrinol., 13: 265-273, 1994.
- Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X. Y., Sauter, G., Kallioniemi, O. P., Trent, J. M., and Meltzer, P. S. AlB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (Washington DC), 277: 965–968, 1997.
- Bautista, S., Valles, H., Walker, R. L., Anzick, S., Zeiłlinger, R., Meltzer, P., and Theillet, C. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin. Cancer Res., 4: 2925–2929, 1998.
- Read, L., Greene, G., and Katzenellenbogen, B. Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists and growth factors. Mol. Endocrinol., 3: 295-304, 1080
- Berkenstam, A., Glaumann, H., Martin, M., Gustafsson, J. A., and Norstedt, G. Hormonal regulation of estrogen receptor messenger ribonucleic acid in T47Dco and MCF-7 breast cancer cells. Mol. Endocrinol.. 3: 22-28, 1989.
- Berry, M., Metzger, D., and Chambon, P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J., 9: 2811–2818. 1990.
- Osborne, C. K. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat., 51: 227–238, 1998.
- Berns, E. M., Van Staveren, I. L., Klijn, J. G., and Foekens, J. A. Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer. Breast Cancer Res. Treat., 48: 87-92, 1998.
- Hermsen, M. A., Baak, J. P., Meijer, G. A., Weiss, J. M., Walboomers, J. W., Snijders, P. J., and van Diest, P. J. Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors. J. Pathol., 186: 356–362, 1998.
- Schwendel, A., Richard, F., Langreck, H., Kaufmann, O., Lage, H., Winzer, K. J., Petersen, I., and Dietel, M. Chromosome alterations in breast carcinomas: frequent involvement of DNA losses including chromosomes 4q and 21q. Br. J. Cancer, 78: 806-811, 1998.
- Tirkkonen, M., Johannsson, O., Agnarsson, B. A., Olsson, H., Ingvarsson, S., Karhu, R., Tanner, M., Isola, J., Barkardottir, R. B., Borg, A., and Kallioniemi, O. P. Distinct somatic genetic changes associated with tumor progression in carriers of *BRCA1* and *BRCA2* germ-line mutations. Cancer Res., 57: 1222–1227, 1997.

⁴ http://www.ncbi.nlm.nih.gov/genemap/loc.cgi?ID=12637.

APPENDIX 3

Increased Expression of the Steroid Receptor RNA Activator (SRA) During Human Breast Tumorigenesis.

Etienne Leygue, Helmut Dotzlaw , Sharon LR Simon, Peter H Watson* and Leigh C Murphy#.

Dept of Biochemistry & Medical Genetics, and Dept of Pathology*, Faculty of Medicine, University of Manitoba, Winnipeg. Manitoba.

Canada. R3E 0W3.

to whom correspondence should be sent:

Telephone: 204-789-3233

Fax: 204-789-3900

E.mail: lcmurph@cc.umanitoba.ca

Keywords: SRA, steroid hormone receptor activator, normal breast, breast tumorigenesis.

Abstract.

Background: SRA, a novel steroid receptor coactivator, which is active as an RNA molecule has recently been identified. Furthermore, we have previously detected the expression of SRA RNA in human breast tumor biopsy samples, which suggested that it could be involved in regulation of steroid hormone receptor activity in human breast cancers. Purpose: Since estrogen receptor-α expression is upregulated in human breast tumorigenesis it was of interest to determine if SRA was expressed in normal human breast tissue and if so was its expression altered in human breast tumors. Methods: Using reverse transcription polymerase chain reaction assays, expression of SRA was compared between adjacent normal human breast tissue and matched breast tumors from 19 patients. Results: Core SRA RNA was detected in both normal and neoplastic breast tissues. The level of SRA RNA was found to be significantly (Wilcoxon matched pairs test, p = 0.0004) higher in breast tumors than in the matched normal breast. A deleted SRA RNA was detected in most samples of normal and neoplastic breast tissues. No differences occurred in the relative expression of the deleted SRA between normal breast and tumors. However, within the breast tumor cohort the relative expression of the deleted SRA was positively correlated with tumor grade (Spearman coefficient, r = 0.556, p = 0.0135) and size (r = 0.655, p = 0.0023). **Conclusion:** Core SRA RNA and a deleted SRA RNA are present in both normal and neoplastic human breast tissues. The expression of SRA is significantly increased in breast tumors compared to the adjacent normal breast tissue. The relative expression of the

deleted SRA was increased in those tumors with markers of a poorer prognosis.

Implications: These data suggest that expression of core SRA is upregulated during breast tumorigenesis and could contribute to altered steroid receptor activity in breast tumors, which may in turn effect hormone responsiveness. Further, changes in the relative expression of a deleted SRA isoform occur during breast cancer progression and may have some role in breast cancer progression.

Introduction.

Recently, a novel steroid receptor coactivator, SRA (1) was isolated and characterized. Interestingly, the available data suggest that the SRA RNA transcript is the functionally important molecule with respect to its steroid receptor activator activity (1) and is found within ribonucleoprotein complexes which may also contain other steroid receptor activators such as SRC-1 (2) which are functional as proteins. Previously, we have detected the expression of SRA RNA in human breast tumor biopsy samples (3). In contrast to another steroid receptor activator, AIB1, whose overexpression is correlated with estrogen (ERα) and progesterone receptor (PR) expression (4) SRA expression was not correlated overall with steroid receptor status as measured by ligand binding assays (3). Although the expression of a deleted form of SRA RNA was found to correlate with increasing tumor grade, the total expression of SRA-like RNA was unrelated to markers of progression and endocrine sensitivity in human breast tumors overall (3). These previous results, however, did not address the possibility that SRA expression could be altered during breast tumorigenesis. Since estrogen receptor signaling is thought to be altered during breast tumorigenesis as well as breast cancer progression, we have tested the hypothesis that altered expression of SRA is associated with breast tumorigenesis and therefore could contribute to altered estrogen signaling during breast tumorigenesis.

Materials and Methods.

Human Breast Tissues.

Nineteen ER positive primary human breast tumor biopsies (ER positivity defined as > 3 fmol/mg protein in classical ligand binding assays) were selected from the National Cancer Institute of Canada-Manitoba Breast Tumor Bank (Winnipeg, Manitoba, Canada). The ER levels ranged from 3.7 - 83 fmol/mg protein and the PR levels ranged from 2.7 - 112 fmol/mg protein (PR positivity defined as > 10 fmol/mg protein in classical ligand binding assays; 14 tumors were PR+ and 5 tumors were PR -). For each case, matched adjacent normal and tumor frozen tissue blocks were available. The quality of each block and the relative cellular composition was determined by the histopathological assessment of sections from adjacent mirror image paraffin-embedded tissue blocks, as previously described (5). The presence of normal ducts and lobules as well as the absence of any atypical lesion was confirmed in all normal tissue specimens. The tumors spanned a wide range of grades (grade scores 5-9) as determined by the Nottingham grading system (6), and ranged in size from 0.6 -6.4 cm.

RNA Extraction and RT-PCR conditions.

Total RNA was extracted from 20 μ m frozen tissue sections (20 sections per tumor; 35 sections for normal tissues) using TrizolTM reagent (Life Technologies, NY) according to the manufacturer's instructions and quantified spectrophotometrically. One μ g of total RNA was reverse transcribed in a final volume of 25 μ l as previously described (7).

Primers and PCR conditions.

The primers SRAcoreU primer (5'used were AGGAACGCGGCTGGAACGA -3'; sense; positions 35-53, Genbank accession number AF092038) and SRAcoreL primer (5'- AGTCTGGGGAACCGAGGAT -3'; antisense; position 696-678, Genbank accession number AF092038). PCR amplifications were performed and PCR products analyzed as previously described (7) with minor modifications. Briefly, 1 µl of reverse transcription mixture was amplified in a final volume of 15 μl, in the presence of 1.5 μCi of $(\alpha-32P)$ dCTP (3000 Ci/mmol), 4 ng/ μ l of each primer and 0.3 unit of Tag DNA polymerase (Gibco BRL, Grand Island, NY). Each PCR consisted of 30 cycles (30 sec at 60°C, 30 sec at 72°C and 30 sec at 94°C). PCR products were then separated on 6% polyacrylamide gels containing 7M urea. Following electrophoresis, the gels were dried and exposed 2 hours to a Molecular ImagerTM-FX Imaging screen (Bio-Rad, Hercules, CA). Amplification of the ubiquitously expressed glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA was performed in parallel and PCR products separated on agarose gels stained with ethidium bromide as previously described (7). Identity of PCR products was confirmed by subcloning and sequencing, as previously reported (8).

Quantification of SRA expression.

Exposed screens were scanned using a Molecular ImagerTM-FX (Bio-Rad, Hercules, CA) and the intensity of the signal corresponding to SRA was measured using Quantity OneTM software (Bio-Rad, Hercules, CA). Three independent PCRs were performed. In order to control for variations between experiments, a value of 100% was arbitrarily assigned to the SRA signal of one particular tumor (tumor #14) measured in each set of PCR experiments

and all signals were expressed as a percentage of this signal. In parallel, *GAPDH* cDNA was amplified and following analysis of PCR products on prestained agarose gels, signals were quantified by scanning using MultiAnalyst™ (Bio-Rad, Hercules, CA). Three independent PCRs were performed. Each *GAPDH* signal was also expressed as a percentage of the signal observed in the tumor #14. For each sample, the average of SRA signal was then expressed as a percentage of the *GAPDH* signal (arbitrary units).

Quantification of the relative expression of the deleted SRA variant RNA.

It has previously been shown that the co-amplification of a wild-type and a deleted variant cDNA resulted in the amplification of two PCR products, the relative signal intensity of which provided a reliable measurement of the relative expression of the deleted variant (8,9). For each sample, SRAdel corresponding signal was measured using Quantity OneTM software (Bio-Rad, Hercules, CA) and expressed as a percentage of the corresponding core SRA signal. For each case, 3 independent assays were performed and the mean determined.

Statistical analysis

Differences between normal samples and their matched tumors were tested using the Wilcoxon matched pairs test, two-tailed. Correlation between SRA expression and tumor characteristics was tested by calculation of the Spearman coefficient r.

Results.

Detection of SRA and a deletion variant RNA form in both normal and neoplastic human breast tissues.

Using the SRA specific primers described in the "Materials and Methods" section, which amplify the core SRA sequences (Figure 1) as described by Lanz *et al.*, (*I*), we have previously detected two PCR products of 662 bp and 459 bp in human breast tumors (*3*). Cloning and sequencing revealed the identity of the 662 bp fragment with the SRA core region (*I*), and the 459 bp fragment as a variant form of SRA deleted in 203 bp between positions 155 and 357 (Figure 1, as numbered according to Genbank accession number AF092038). The current analysis identified the 662 bp product in all breast tissue samples assayed, both normal and neoplastic. As well, a 459 bp product corresponding to a SRA transcript deleted in 203 nucleotides was detected in the majority of tumors (n = 18) and normal samples (n = 17), and always together with the 662 bp product (Figure 2). Therefore, SRA core sequences are expressed in all human breast tissues and the expression of the deleted SRA transcript is not tumor specific.

Comparison of the expression of SRA and deleted SRA in adjacent normal breast tissue and matched primary breast tumors.

To determine whether alterations in core SRA expression occur during breast tumorigenesis, the expression of SRA RNA was measured in primary tumor tissues and their adjacent matched normal breast tissues from 19 different patients, as described in the Materials and Methods section. The analysis was confined to tissues from women whose breast tumor was ER+, as determined by ligand binding assays. Examples of the results obtained are shown in Figure 2. The expression of SRA corrected for the *GAPDH* signal in

each tissue sample for all the matched normal and tumor pairs is shown as a scatter graph in Figure 3A. The level of expression of core SRA was found to be significantly higher (Wilcoxon matched pairs test, p = 0.0004) in the tumor samples compared to their adjacent normal breast tissue. When the deleted SRA is detected, the expression of the variant SRA transcript relative to the core SRA expression was not significantly different between normal breast tissues and their matched adjacent breast tumors (Figure 3B). These data suggest that core SRA expression is upregulated during breast tumorigenesis, but the relative expression of a deleted SRA variant is not altered during breast tumorigenesis.

Correlation of SRA expression and the relative expression of deleted SRA with tumor characteristics.

The level of core SRA expression in the tumor cohort used in this study was not correlated with PR status, grade, tumor size or nodal status. However, the relative expression of the deleted SRA transcript in the tumors was positively correlated with grade score (Spearman r = 0.556, p = 0.0135), and tumor size (Spearman r = 0.655, p = 0.0023) but was not correlated with PR status or nodal status. These data suggest that increased relative expression of a deleted SRA variant is more likely to occur in those breast tumors with characteristics of a poorer prognosis, and may be associated with breast tumor progression.

Discussion.

SRA is a novel steroid hormone receptor activator. In particular it is different from other steroid receptor coactivators in three important ways: firstly it functions as a RNA molecule rather than a protein; secondly, it is specific for steroid hormone receptors; and thirdly, rather than effecting AF2 of steroid hormone receptors, it is specific for the AF1 domain of these receptors (1).

Since steroid hormones, in particular estrogen, play an important role(s) in the growth and function of both the normal and neoplastic human breast (10,11)and since altered estrogen receptor signaling likely occurs both in breast tumorigenesis and breast cancer progression (12-15), alteration of factors which may influence ER activity during breast tumorigenesis and/or progression are highly relevant to investigate in human breast tumorigenesis in vivo (16,17). Moreover, there are data which support increased expression of at least one steroid receptor activator, AIB1, in human breast cancers in vivo (18). However, AIB1 functions as a protein, and its site of action is associated with the ligand activated AF2 function of nuclear receptors generally (18,19). In contrast, SRA's site of action is the ligand independent AF1 function (1) of steroid hormone receptors, which in the case of ER α is thought to be important for cross-talk between growth factor/MAP kinase pathways (20,21), and is likely involved in mediating the agonist activity of antiestrogens such as tamoxifen. This underscores the importance of investigating factors which modulate specifically the AF1 activity of steroid hormone receptors in human breast tumorigenesis since marked alterations in estrogen and antiestrogen responsiveness are known to occur during breast tumorigenesis and breast cancer progression. Furthermore, antiestrogens such as tamoxifen have recently been shown to be efficacious in the prevention of breast cancer (22), an understanding of the expression and role of factors likely to effect tissue responsiveness to estrogens and antiestrogens in human breast is absolutely necessary.

The data presented in our study suggest that the expression of the SRA is significantly increased in ER positive human breast tumors *in vivo* compared to their adjacent matched normal breast tissue. Since SRA is functional as a steroid receptor activator as a RNA molecule (*I*), measurement of the level of

SRA RNA likely reflects functional equivalents of this molecule in the breast tissues, and therefore our data support the hypothesis that the activity of this receptor activator is significantly upregulated during human breast tumorigenesis and therefore may have a role in increasing estrogen receptor signal transduction and sensitivity during breast tumorigenesis. Interestingly, our previous data (3) suggest that the level of expression of SRA in primary tumors, in contrast to AIB1 (4), is not correlated with ER and PR status overall, which suggests that SRA may subserve other functions in ER and PR negative tumors compared to ER and PR positive tumors. However, subgroup analysis within a previous cohort (3) showed that SRA expression correlated with either ER or PR depending on the subgroup considered. The general trend was that in tumors with a low level of expression of one receptor either ER or PR, a positive correlation was found between SRA and the second receptor, either PR or ER. In contrast in tumors expressing a high level of one receptor, either ER or PR, a negative correlation of SRA expression with the level of expression of the second receptor, either PR or ER was found. The functional significance of such correlations is unclear at this stage, but may reflect compensatory regulation under conditions of potentially reduced steroid responsiveness.

We have found no correlations of SRA expression with different percentages of epithelial and stromal cell types in either the normal or the tumor compartments of this cohort (data not shown), suggesting that differences in proportions of cell types and cellularity amongst the tissues is unlikely to explain the results obtained. Previously, SRA was shown to be expressed in human breast cancer cell lines in culture (1), consistent with the idea that SRA is expressed in epithelial cells. Our data are consistent with this observation and together the data support the hypothesis that the expression

of SRA is increased significantly in human breast cancer cells both in vivo and in culture.

At least three isoforms of SRA RNA, containing the so-called core region (see Figure 1) but differing in the regions outside of the core region, both 5' and 3', were reported previously (1). It is the core region of SRA which is necessary and sufficient for the steroid receptor activator activity of SRA. The design of our primers for SRA as previously described (3), will detect all SRA isoforms containing core sequences. In the absence of data characterizing potential individual functions of SRA isoforms differing in the 5' and 3' regions outside of an intact core region, we assume that our measurement of all intact core SRA like RNAs correlates with the total SRA activity present in any one tissue sample. These primers, however, also detect a distinct but previously described isoform of SRA (Genbank accession number AA426601) containing a deletion of sequences within the SRA core region. Deletions within the core region were previously reported to result in loss of SRA activator function (1). Although the specific deletion found in the naturally occurring SRA deleted variant RNA has not been characterized per se, the currently published data suggest that it is likely that this deleted variant is inactive with respect to steroid receptor activator activity. It could therefore function to alter steroid signaling pathways in human breast tumors and may contribute to the more aggressive phenotype associated with poorer prognosis breast tumors, which include characteristics such as high grade and large tumor size.

In conclusion our data support a significant upregulation of total core SRA-like expression and likely activity during human breast tumorigenesis. This upregulation, in combination with that of other steroid receptor activators and increased expression of $ER\alpha$ are all likely to contribute to altered

estrogen sensitivity which occurs during and possibly contributes to human breast tumorigenesis.

Notes.

This work was supported by grants from the Canadian Breast Cancer Research Initiative (CBCRI) and the Medical Research Council of Canada. The Manitoba Breast Tumor Bank is supported by funding from the National Cancer Institute of Canada (NCIC). LCM is a Medical Research Council of Canada (MRC) Scientist, PHW is a MRC Scientist, EL is a recipient of a USAMRMC Postdoctoral Fellowship. The authors thank Linda Snell and Sandra Troup for processing the tissue blocks and cutting the tissue sections.

References.

- (1) Lanz R, McKenna N, Onate S, et al: A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 97:17-27, 1999
- (2) Onate SA, Tsai SY, Tsai MJ, et al: Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-1357, 1995
- (3) Leygue E, Dotzlaw H, Watson P, et al: Expression of the steroid receptor RNA activator (SRA) in human breast tumors. Cancer Res 59:4190-4193, 1999
- (4) Bautista S, Valles H, Walker R, et al: In breast cancer, amplification of the steroid receptor coactivator gene AlB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 4:2925-2929., 1998
- (5) Hiller T, Snell L, Watson P: Microdissection/RT-PCR analysis of gene expression. Biotechniques 21:38-44, 1996
- (6) Elston C, Ellis I: Pathological prognostic factors in breast cancer. Histopathology 19:403-410, 1991
- (7) Leygue E, Murphy L, Kuttenn F, et al: Triple primer polymerase chain reaction. A new way to quantify truncated mRNA expression. Am J Pathol 148:1097-1103, 1996
- (8) Leygue ER, Watson PH, Murphy LC: Estrogen receptor variants in normal human mammary tissue. J Natl Cancer Inst 88:284-290, 1996
- (9) Daffada AA, Johnston SR, Nicholls J, et al: Detection of wild type and exon 5-deleted splice variant oestrogen receptor (ER) mRNA in ER-positive and -negative breast cancer cell lines by reverse transcription/polymerase chain reaction. J Mol Endocrinol 13:265-273, 1994
- (10) Kelsey J, Gammon M, John E: Reproductive and hormonal risk factors: reproductive factors and breast cancer. Epidemiologic Reviews 15:36-47, 1993
- (11) Bocchinfuso W, Korach K: Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia 2:323-334, 1997

- (12) Khan SA, Rogers MA, Obando JA, et al: Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 54:993-997, 1994
- (13) Leygue E, Dotzlaw H, Watson P, et al: Altered estrogen receptor alpha and beta mRNA expression during human breast tumorigenesis. Cancer Res 58:3197-3201, 1998
- (14) Shoker B, Jarvis C, Sibson D, et al: Oestrogen receptor expression in the normal and precancerous breast. J Pathol 188:237-244, 1999
- (15) Murphy L: Mechanisms of Hormone Independence in Human Breast Cancer. In Vivo 12:95-106, 1998
- (16) Lavinsky R, Jepsen K, Heinzel T, et al: Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A 95:2920-5, 1998
- (17) McInerney EM, Tsai MJ, O'Malley BW, et al: Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc Natl Acad Sci U S A 93:10069-73, 1996
- (18) Anzick S, Kononen J, Walker R, et al: AlB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965-968, 1997
- (19) McKenna N, Lanz R, O'Malley B: Nuclear receptor coregulators: cellular and molecular biology. Endocrine Rev 20:321-344, 1999
- (20) El-Tanani M, Green C: Two separate mechanisms for ligand independent activation of the estrogen receptor. Mol Endocrinol 11:928-937, 1997
- (21) Kato S, Endoh H, Masuhiro Y, et al: Activation of the estrogen receptor through phosphorylation by mitgen activated protein kinase. Science 270:1491-1494, 1995
- (22) Fisher B, Constantino J, Wickerham D, et al: Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388, 1998

Legends to Figures.

Figure 1.

Primers and expected PCR products for core SRA and deleted SRA. SRAcoreU and SRAcoreL primers anneal with SRA core sequences (white boxes, bases 28-720, see reference 1) and allow the amplification of a 662 bp and a 459 bp long fragment corresponding to the wild-type SRA core mRNA and a SRA mRNA deleted from bases 155 to 357 (SRAdel, see reference 3), respectively. The 5' and 3' variable regions of the different SRA isoforms previously identified (1) are indicated by gray boxes.


Figure 2.


Detection of SRA in normal breast tissue adjacent to matched primary, ER+ invasive breast cancer. RNA extracted from matched breast tumors and adjacent matched normal breast tissue was extracted from 19 different patients and assayed for SRA expression using RT-PCR as described in Materials and Methods. PCR products were separated on 6% acrylamide gels, which were dried, exposed to phosphor-imaging screens, and scanned using a Molecular ImagerTM-FX. A. A digitized image showing the results obtained from 4 sets of normal tissue (N) and matched tumor tissue (T) is shown. The arrows identify the expected 662 bp core SRA PCR product (SRA core, confirmed by sequence analysis) and a 459 bp deleted SRA variant PCR product (SRAdel), which was identified by sequence analysis to correspond to an SRA variant deleted in sequences from position 155 to 357 (Genbank accession number AF092038). **B.** Ethidium bromide stained gel of the RT-PCR analysis of GAPDH mRNA run in parallel for the same samples. The arrow identifies the expected 178 bp GAPDH PCR product.


Figure 3.

- A. Comparison of the expression of SRA in adjacent normal breast tissue and matched primary breast tumors. For each patient (n = 19), SRA expression was quantified and expressed in arbitrary units corrected for *GAPDH* signal as described in the Materials and Methods. The results are presented as a scatter graph. The normal samples are represented by open squares and the tumor samples by filled squares. Each matched normal and tumor sample is joined by a line. The level of SRA expression in normal tissue is significantly different to the level of SRA expression in the tumor tissues (Wilcoxon matched pairs test, two-tailed, p = 0.0004).
- B. Comparison of the relative expression of the deleted SRA variant in adjacent normal breast tissue and matched primary breast tumors. For each sample, the signal corresponding to the deleted SRA variant RNA (SRAdel) was measured using Quantity OneTM software (Bio-Rad, Hercules, CA) and expressed as a percentage of the corresponding core SRA signal as described in the Materials and Methods. The results are presented as a scatter graph. The normal samples are represented by open squares and the tumor samples by filled squares. Each matched normal and tumor sample is joined by a line. There is no significant difference between the relative expression of SRAdel in normal samples and their matched adjacent tumors.

Figure 1.







APPENDIX 4

DO NOT FOLD

FOR OFFICE USE ONLY

ANNUAL MEETING April 1-5, 2000

The Moscone Center • San Francisco, CA

Deadline: November 1, 1999 Enclose:

- ☐ Original abstract form. (This form must be filled out and signed completely.)
- Check for US\$40 payable to AACR, Inc., OR authorization to charge US\$40 to credit card (see Item 8, below.).
- A completed and signed original of the Copyright Transfer/Disclosure form.
- Category and Subclassification (see pages 10-12): Type the five-character code in the blocks provided.

E	N	1	-	1	4

2. Abstract is SPONSORED by:

Abstract Form

Expression of a Repressor of Estrogen Receptor (ER) Activity (REA) in Human Breast Tissues. Simon SLR, Parkes A, Leygue E, Dotzlaw H, Watson PH*, Murphy LC. Dept of Biochemistry & Medical Genetics; *Dept of Pathology, University of Manitoba, Winnipeg, Canada. R3E 0W3.

ER α & some coactivators are upregulated during breast tumorigenesis. Recently, REA/BAP37 was identified as a repressor of ER. It was relevant therefore to determine if REA was expressed in breast tissue & if so was its expression altered during tumorigenesis. We measured REA mRNA levels in normal & neoplastic human breast tissues. A single ~1.7 kb REA mRNA was identified by Northern blot in breast cancer cells and biopsies. REA mRNA was measured by RT-PCR in ER+ breast tumors & matched adjacent normal tissue. Some breast tumors (12/19) contained higher levels of REA mRNA than their normal tissues, but this was not statistical significant, although SRA mRNA, an ER coactivator, was significantly increased in tumors vs matched normal tissue in this set (Wilcoxon, P=0.0004). REA mRNA levels varied amongst tumors and were found to be positively correlated (Spearman r=0.323, P=0.042) with ER level (determined by ligand binding) and inversely correlated with grade (Spearman r=-0.438, P=0.0054). However, estrogen did not regulate REA mRNA expression in MCF7 cells. These data suggest that while REA expression may not be altered in early breast tumorigenesis, altered regulation may contribute to breast cancer progression.

Type abstract within black lines. See sample abstract.

	(See Directory	of Members for M	ember No.)
LEIGH C. N	NURPHY		Name
(Please Print)	,		
DEPT. BIOCH	EM 4 MED	GENETICS	Address
UNIV. OF W	1ANITOBA		
WINNIPEG	MB		City, State
RZEOWZ	Zip/Postal Code	CANADA	_Country
4-189-3233	Telephone No.	789-3900	_ FAX No.
LCMURPHO C	c. umanito	ba.ca E-Mi	ail Address
4. (Complete only if SPONS Active or Corresponding or Honorary Member, er which the above-named (See regulations applying	Member in good st ndorse the conter Associate Membe	e Member) I, the warding, Emeritus at of this abstracter is sponsor and	ndersigned Member, , for
			Name
(Please Print)	Signature	M	lember No

4623

Member No.

Eligibility for Young Investigator Awards (American and International)
 The PRESENTER of this abstract is a medical or graduate student, medical resident, or postdoctoral or clinical fellow.

□ B. The PRESENTER meets the criteria in Box A above and is also a minority scientist as defined by the National Cancer Institute (see page 7).

☐ C. The PRESENTER of this abstract is a full-time faculty member at a Historically Black College or University (HBCU).

6. Abstract to be PRESENTED by	Member No.	
SHARON LR	(If an AACR Member.) SIMON.	Name
(Please Print)		
SAME AS SPO	onsor	Addres
		City, State
Zip/Po	stal Code	Country
	hone No.	FAX No
rennie 61 @cc. ur	manitoba.ca	_E-Mail Addres

7. As the PRESENTER and as an author of this abstract and on behalf of all the authors, I hereby give exclusive permission to the American Association for Cancer Research, Inc. to record my presentation at the 2000 Annual Meeting and to collect all revenue from subsequent audiocassette sales. I also acknowledge that I am enclosing a completed, signed original of the Copyright Transfer/Disclosure Form.

Signature of PRESENTER

- 8. Payment of US\$40 Abstract Submission Fee.
- $\hfill \Box$ Check is enclosed. Please list name of PRESENTER on the check.
- □ I authorize you to charge my credit card for the abstract submission fee.
 □ VISA
 □ MasterCard
 □ American Express

	Expiration Date
Card No.	Expiration Date

Cardholder Name (PRINT)

Signature

Please check all the information you have entered for correctness and adherence to AACR submission rules. Infractions of sponsorship regulations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. Infractions of format, including forms submitted without the required signatures, will result in a fee of US\$40 which will be billed to the SPONSOR.

DEPARTMENT OF THE ARMY



US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 504 SCOTT STREET FORT DETRICK, MARYLAND 21702-5012

REPLY TO ATTENTION OF:

MCMR-RMI-S (70-1y)

21 Feb 03

MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl

PHYLYS M / RINEHART

Deputy Chilef of Staff for Information Management

ADB263458	ADB282838
ADB282174	ADB233092
ADB270704	ADB263929
ADB282196	ADB282182
ADB264903	ADB257136
ADB268484	ADB282227
ADB282253	ADB282177
ADB282115	ADB263548
ADB263413	ADB246535
ADB269109	ADB282826
ADB282106	ADB282127
ADB262514	ADB271165
ADB282264	ADB282112
ADB256789	ADB255775
ADB251569	ADB265599
ADB258878	ADB282098
ADB282275	ADB232738
ADB270822	ADB243196
ADB282207	ADB257445
ADB257105	ADB267547
ADB281673	ADB277556
ADB254429	ADB239320
ADB282110	ADB253648
ADB262549	ADB282171
ADB268358	ADB233883
ADB257359	ADB257696
ADB265810	ADB232089
ADB282111	ADB240398
ADB273020	ADB261087
ADB282185	ADB249593
ADB266340	ADB264542
ADB262490	ADB282216
ADB266385	ADB261617
ADB282181	ADB269116
ADB262451	
ADB266306	
ADB260298	
ADB269253	
ADB282119	
ADB261755	
ADB257398	
ADB267683	
ADB282231	
ADB234475	
ADB247704	
ADB258112	
ADB267627	